These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 9255270)

  • 1. Prognostic factors and prognostic staging system for small cell lung cancer.
    Kawahara M; Fukuoka M; Saijo N; Nishiwaki Y; Ikegami H; Tamura T; Shimoyama M; Suemasu K; Furuse K
    Jpn J Clin Oncol; 1997 Jun; 27(3):158-65. PubMed ID: 9255270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alternating chemotherapy with cyclophosphamide, doxorubicin, vincristine and cisplatin, etoposide followed by prophylactic cranial and thoracic irradiation for small cell lung cancer (SCLC): long-term results.
    Ardizzoni A; Fusco V; Pennucci C; Baldini E; Orsatti M; Vitale V; Bonavia M; Baracco F; Mereu C; Rosso R
    Anticancer Res; 1991; 11(2):681-4. PubMed ID: 1648333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial.
    Wolf M; Havemann K; Holle R; Gropp C; Drings P; Hans K; Schroeder M; Heim M; Dommes M; Mende S
    J Clin Oncol; 1987 Dec; 5(12):1880-9. PubMed ID: 2824710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Small cell lung carcinoma: role of thoracic irradiation and its timing in relation to chemotherapy].
    Payne DG; Murray N; Warde P
    Bull Cancer; 1994 Feb; 81(2):119-28. PubMed ID: 7894117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A retrospective analysis of patients receiving surgery after chemotherapy for small cell lung cancer.
    Yamada K; Saijo N; Kojima A; Ohe Y; Tamura T; Sasaki Y; Eguchi K; Shinkai T; Goya T; Kondou H
    Jpn J Clin Oncol; 1991 Feb; 21(1):39-45. PubMed ID: 1648633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study.
    Goodman GE; Crowley JJ; Blasko JC; Livingston RB; Beck TM; Demattia MD; Bukowski RM
    J Clin Oncol; 1990 Jan; 8(1):39-47. PubMed ID: 2153194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group.
    Murray N; Livingston RB; Shepherd FA; James K; Zee B; Langleben A; Kraut M; Bearden J; Goodwin JW; Grafton C; Turrisi A; Walde D; Croft H; Osoba D; Ottaway J; Gandara D
    J Clin Oncol; 1999 Aug; 17(8):2300-8. PubMed ID: 10561291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine.
    Johnson BE; Bridges JD; Sobczeck M; Gray J; Linnoila RI; Gazdar AF; Hankins L; Steinberg SM; Edison M; Frame JN; Pass H; Nesbitt J; Holden D; Mulshine JL; Glatstein E; Ihde DC
    J Clin Oncol; 1996 Mar; 14(3):806-13. PubMed ID: 8622028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of limited-stage small-cell lung cancer with cyclophosphamide, doxorubicin, and vincristine with or without etoposide: a randomized trial of the North Central Cancer Treatment Group.
    Jett JR; Everson L; Therneau TM; Krook JE; Dalton RJ; Marschke RF; Veeder MH; Brunk SF; Mailliard JA; Twito DI
    J Clin Oncol; 1990 Jan; 8(1):33-8. PubMed ID: 2153193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of age on the treatment of limited-stage small-cell lung cancer.
    Siu LL; Shepherd FA; Murray N; Feld R; Pater J; Zee B
    J Clin Oncol; 1996 Mar; 14(3):821-8. PubMed ID: 8622030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-intensive weekly alternating chemotherapy for patients with small cell lung cancer: randomized trial, can it improve survival of patients with good prognostic factors?
    Masutani M; Ochi Y; Kadota A; Akusawa H; Kisohara A; Takahashi N; Koya Y; Horie T
    Oncol Rep; 2000; 7(2):305-10. PubMed ID: 10671676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishment of tumor cell lines as an independent prognostic factor for survival time in patients with small-cell lung cancer.
    Masuda N; Fukuoka M; Matsui K; Kusunoki Y; Kudoh S; Negoro S; Takifuji N; Fujisue M; Morino H; Nakagawa K
    J Natl Cancer Inst; 1991 Dec; 83(23):1743-8. PubMed ID: 1663169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of cyclophosphamide, doxorubicin, and vincristine with an alternating regimen of methotrexate, etoposide, and cisplatin/cyclophosphamide, doxorubicin, and vincristine in the treatment of extensive-disease small-cell lung carcinoma: a Mid-Atlantic Oncology Program study.
    Wampler GL; Heim WJ; Ellison NM; Ahlgren JD; Fryer JG
    J Clin Oncol; 1991 Aug; 9(8):1438-45. PubMed ID: 1649265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group.
    Furuse K; Fukuoka M; Nishiwaki Y; Kurita Y; Watanabe K; Noda K; Ariyoshi Y; Tamura T; Saijo N
    J Clin Oncol; 1998 Jun; 16(6):2126-32. PubMed ID: 9626212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up.
    Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Hatlevoll R; Dahle R; Boye N; Wang M; Vigander T; Vilsvik J; Skovlund E; Hannisdal E; Aamdal S;
    J Clin Oncol; 2002 Dec; 20(24):4665-72. PubMed ID: 12488411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic influence of TNM staging and LDH levels in small cell carcinoma of the lung (SCCL).
    Byhardt RW; Hartz A; Libnoch JA; Hansen R; Cox JD
    Int J Radiat Oncol Biol Phys; 1986 May; 12(5):771-7. PubMed ID: 3011712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of small cell lung cancer in the elderly.
    Shepherd FA; Amdemichael E; Evans WK; Chalvardjian P; Hogg-Johnson S; Coates R; Paul K
    J Am Geriatr Soc; 1994 Jan; 42(1):64-70. PubMed ID: 8277118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternating chemotherapy and thoracic radiotherapy with concurrent cisplatin-etoposide for limited-stage small-cell carcinoma of the lung.
    Murray N; Shah A; Brown E; Kostashuk E; Laukkanen E; Goldie J; Band P; Van den Hoek J; Murphy K; Sparling T
    Semin Oncol; 1986 Sep; 13(3 Suppl 3):24-30. PubMed ID: 3020695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer.
    Fukuoka M; Furuse K; Saijo N; Nishiwaki Y; Ikegami H; Tamura T; Shimoyama M; Suemasu K
    J Natl Cancer Inst; 1991 Jun; 83(12):855-61. PubMed ID: 1648142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized trial comparing weekly versus 3-week chemotherapy in small-cell lung cancer: a Cancer Research Campaign trial.
    Souhami RL; Rudd R; Ruiz de Elvira MC; James L; Gower N; Harper PG; Tobias JS; Partridge MR; Davison AG; Trask C
    J Clin Oncol; 1994 Sep; 12(9):1806-13. PubMed ID: 8083704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.